NUCLEAR β-CATENIN INHIBITOR – TBL1 – A Novel Target for Safe & Effective Blockade of the Nuclear β-catenin Signaling Pathway& Effective Blockade Of The Nuclear Β-Catenin Signaling Pathway
Ruolan Han, PhD
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings.